{
  "abstract": "Narcolepsy is a rare disorder of central hypersomnolence which is often under-recognised owing to a variable clinical phenotype. Narcolepsy type 1 (NT1) is caused by loss of hypothalamic hypocretin (orexin) secreting neurons, which function to maintain wakefulness. There is strong evidence that NT1 is an immune-mediated disorder associated with the class II human leucocyte antigen DQB1*06:02 allele. Immune checkpoint inhibitors have revolutionised the treatment of many cancers; however, through their mechanism of action, they are associated with immune-related adverse effects. We describe a complex case of NT1 following ipilimumab and nivolumab exposure for management of metastatic melanoma.",
  "authors": [
    {
      "affiliations": [
        "Respiratory and Sleep Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia"
      ],
      "name": "Aiden Cushnahan"
    },
    {
      "affiliations": [
        "Respiratory and Sleep Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia"
      ],
      "name": "Su Hii"
    },
    {
      "affiliations": [
        "Respiratory and Sleep Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia",
        "Monash University, Melbourne, Victoria, Australia"
      ],
      "name": "Kirk Kee"
    },
    {
      "affiliations": [
        "Respiratory and Sleep Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia",
        "University of Melbourne, Melbourne, Victoria, Australia"
      ],
      "name": "Megan Rees"
    },
    {
      "affiliations": [
        "Respiratory and Sleep Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia"
      ],
      "name": "Peter Wallbridge"
    }
  ],
  "title": "Narcolepsy type 1 following immune checkpoint inhibitor therapy for metastatic melanoma",
  "uid": "1a9da5ba-9ce5-5497-b129-500f9b8c6af3"
}